Phase 2 Study presented during the 56th American Society of Hematology (ASH) Annual Meeting & Exposition

We would like to share an important update regarding the preliminary results from a Phase 2 Study presented during the 56th American Society of Hematology (ASH) Annual Meeting & Exposition on 7 December 2014 in San Francisco. The recent data have shown that Luspatercept (ACE-536) has increased Hemoglobin and decreased the transfusion burden and serum ferritin levels in Adults with Beta-Thalassemia. We are very excited about the data and looking forward to the advancement of the program to Phase 3 next year!

 

Read more on the ASH website at :

http://www.hematology.org/Annual-Meeting/